Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jan 2024 17:30

Arix Bioscience PLC (ARIX) Holding(s) in Company 24-Jan-2024 / 17:30 GMT/BST


TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Arix Bioscience Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify) iii:

 

3. Details of person subject to the notification obligation iv

Name

RTW Investments, LP

City and country of registered office (if applicable)

New York, USA

4. Full name of shareholder(s) (if different from 3.) v

Name

RTW Biotech Opportunities Operating Ltd

City and country of registered office (if applicable)

St Peter Port, Guernsey

5. Date on which the threshold was crossed or reached vi:

17/01/2024

6. Date on which issuer notified (DD/MM/YYYY):

22/01/2024

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

25.52

0.00%

25.52%

33,023,210

Position of previous notification (if

applicable)

n/a

n/a

n/a

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BD045071

0

33,023,210

0.00%

25.52%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

33,023,210

25.52%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/ Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Roderick Wong

 

 

 

RTW Investments GP LLC

 

 

 

RTW Investments, LP

 

 

 

RTW Biotech Opportunities Ltd

 

 

 

RTW Biotech Opportunities Operating Ltd

25.52%

0.00%

25.52%

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information xvi

 

         

 

Place of completion

London, UK

Date of completion

19/01/2024

 

 

 

 

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 2.3. Major shareholding notifications
Sequence No.:299502
EQS News ID:1822379
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
21st Feb 20187:00 amRNSArix Bioscience and Ipsen sign strategic agreement
19th Feb 20187:00 amRNSArix signs strategic agreement with Fosun
4th Jan 20182:00 pmRNSCEO Letter to Shareholders
3rd Jan 20189:46 amRNSVoting Rights and Capital: Month End Disclosure
22nd Dec 20177:00 amRNSIssue of Ordinary Shares, TVR, PDMR Shareholding
21st Dec 20177:00 amRNSArix co-leads $30m financing for Aura Biosciences
4th Dec 20177:00 amRNSArix Bioscience leads $30m financing for Atox Bio
10th Nov 20179:00 amRNSSir John Banham retires from Board of Directors
1st Nov 20177:00 amRNSArix to present at two IR conferences
18th Oct 20171:31 pmRNSArix notes Harpoon AbbVie IO collaboration
17th Oct 20177:10 amRNSDirector Declaration
17th Oct 20177:00 amRNSGiles Kerr Appointed to Board of Directors
10th Oct 20177:00 amRNSArix Bioscience notes positive data from Amplyx
26th Sep 20177:00 amRNSArix participates in $80 million Autolus financing
18th Sep 20177:20 amRNSClinical progress from Autolus
18th Sep 20177:00 amRNSCapital Markets Meeting Today
14th Sep 20177:00 amRNSArix Bioscience Capital Markets Meeting
8th Sep 20174:27 pmRNSArix to present at Rodman & Renshaw conference
7th Sep 20172:00 pmRNSArix notes positive Verona data in COPD
4th Sep 20177:05 amRNSArix Bioscience notes Artios CSO Appointment
2nd Aug 20177:00 amRNSArix participates in $67m financing for Amplyx
31st Jul 20177:00 amRNSReport for the Six Months Ended 30 June 2017
27th Jul 20177:00 amRNSArix Bioscience: $29M Series A for PreciThera
21st Jul 20173:17 pmRNSMeghan FitzGerald appointed to Board of Directors
17th Jul 20177:00 amRNSNotice of Results
10th Jul 20177:00 amRNSArix Bioscience plc Appoints General Counsel
28th Jun 20177:00 amRNSArix Bioscience leads $45M financing round
27th Jun 201712:00 pmRNSArix Bioscience in $20M Mitoconix Bio fundraise
12th Jun 20177:01 amRNSArix notes Artios collaboration
5th Jun 20173:45 pmRNSResult of AGM
5th Jun 20177:00 amRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSArix to present at Jefferies Healthcare Conference
30th May 20177:00 amRNSDirector/PDMR Shareholding
30th May 20177:00 amRNSAppointment of Jefferies and Stifel as brokers
26th May 20174:35 pmRNSPrice Monitoring Extension
25th May 20177:00 amRNSArix Bioscience Leads Harpoon Therapeutics Round
19th May 20177:00 amRNSArix leads $65m Series B investment for Iterum
9th May 20177:00 amRNSDirector share purchases
28th Apr 201712:04 pmRNSArix Notes Verona's NASDAQ Listing
28th Apr 20178:00 amRNSAnnual Financial Report
18th Apr 201712:00 pmRNSGroup business Verona receives IND for RPL554
31st Mar 20177:00 amRNSBoard Committee Changes
22nd Mar 20172:52 pmRNSHolding(s) in Company
20th Mar 20177:05 amRNSArix Bioscience, LDC, Leeds University Agreement
20th Mar 20177:02 amRNSPartial Exercise of Over-Allotment Option
20th Mar 20177:01 amRNSEnd of Stabilisation Notice
20th Mar 20177:00 amRNSMid-Stabilisation Period Announcement
10th Mar 20174:30 pmRNSMid-Stabilisation Period Announcement
10th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20177:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.